Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence. // JCA Advances. – URL: https://www.sciencedirect.com/science/article/pii/S295055342600081X?dgcid=rss_sd_all
Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence. JCA Advances. https://www.sciencedirect.com/science/article/pii/S295055342600081X?dgcid=rss_sd_all
“Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence.” JCA Advances.
@article{article51007,
title = {Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence},
journal = {JCA Advances},
url = {https://www.sciencedirect.com/science/article/pii/S295055342600081X?dgcid=rss_sd_all}
}